Sarecycline

Analysis of treatment patterns over up to 40 weeks of sarecycline use showed sustained acne control in many patients, low discontinuation rates due to adverse events, and infrequent serious or severe treatment-related events, supporting the medication’s tolerability in extended use among generally healthy individuals with acne.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

In 391 Chinese patients aged 9–45 years with moderate-to-severe acne, once-daily weight-based sarecycline for 12 weeks significantly reduced facial inflammatory lesion counts and increased investigator global assessment success rates compared with placebo; benefits were evident by week 3 and generally maintained over a 36-week open-label extension with few treatment-related adverse events.

Analysis of treatment patterns over up to 40 weeks of sarecycline use showed sustained acne control in many patients, low discontinuation rates due to adverse events, and infrequent serious or severe treatment-related events, supporting the medication’s tolerability in extended use among generally healthy individuals with acne.

In 391 Chinese patients aged 9–45 years with moderate-to-severe acne, once-daily weight-based sarecycline for 12 weeks significantly reduced facial inflammatory lesion counts and increased investigator global assessment success rates compared with placebo; benefits were evident by week 3 and generally maintained over a 36-week open-label extension with few treatment-related adverse events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

Ongoing randomized trial in acne patients is comparing sarecycline versus doxycycline over four weeks, with primary outcomes focused on changes in gut tetracycline-resistant bacteria and fungi/yeast, aiming to clarify the microbiome impact of narrow-spectrum sarecycline relative to a broader-spectrum tetracycline.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

In 391 Chinese patients aged 9–45 years with moderate-to-severe acne, once-daily weight-based sarecycline for 12 weeks significantly reduced facial inflammatory lesion counts and increased investigator global assessment success rates compared with placebo; benefits were evident by week 3 and generally maintained over a 36-week open-label extension with few treatment-related adverse events.

In a 40-week open-label extension involving 483 patients with moderate-to-severe acne who had completed prior 12-week phase 3 sarecycline trials, once-daily sarecycline demonstrated a favorable long-term safety profile, with most adverse events being mild and no new safety signals emerging over extended use.

Across two identically designed 12-week trials in patients aged 9–45 years with moderate-to-severe facial acne, sarecycline 1.5 mg/kg/day significantly reduced inflammatory and noninflammatory lesion counts and improved global acne severity compared with placebo, with a safety profile characterized mainly by mild gastrointestinal and upper respiratory events.